Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2019

27.11.2017 | Original Research

Disregulation of miR-216a and miR-217 in Gastric Cancer and Their Clinical Significance

verfasst von: Reza Safaralizadeh, Naser Ajami, Masoumeh Nemati, Mohammadali Hosseinpourfeizi, Arash Azimzadeh Isfanjani, Seyed-Yaghob Moaddab

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

The majority of gastric cancer (GC) diagnoses occur at the middle or late stage of the disease, indicating that finding novel biomarkers that could be detectable at earlier stage is urgently needed. Accumulating studies have shown that microRNAs, a class of tiny single-stranded RNAs, play important roles in multiple biological processes including cancer development. The present study aimed to evaluate the effect of miR-216a and miR-217 in GC.

Material and Methods

The real-time quantitative reverse-transcription PCR was exploited to identify and compare the expression levels of miR-216a and miR-217 in 37 pairs of samples of gastric cancer tissue and adjacent normal tissue. Superimposed on this, the potential relationship between miR-216a/217 levels and clinicopathological parameters in patients suffering GC was explored.

Results

The results obtained from this study showed that the miR-216a is significantly upregulated in gastric cancer tissues, compared with adjacent normal tissues, but the altered expression of miR-217 was not significant. For miR-216a/217, no significant correlations were detected between expression levels of these miRNAs and clinical and pathological characteristics of patients.

Conclusion

This prospective study proposes that upregulation of miR-216a might represent an important mechanism for the development of gastric cancer.
Literatur
2.
Zurück zum Zitat Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576–83.PubMed Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576–83.PubMed
9.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMed Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMed
10.
Zurück zum Zitat Felekkis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236–40.PubMedPubMedCentral Felekkis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236–40.PubMedPubMedCentral
15.
Zurück zum Zitat Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011;31(12):4387–92.PubMed Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011;31(12):4387–92.PubMed
16.
Zurück zum Zitat Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27–39.PubMedPubMedCentral Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27–39.PubMedPubMedCentral
17.
Zurück zum Zitat Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2013;26(2):155–65.CrossRefPubMed Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2013;26(2):155–65.CrossRefPubMed
20.
Zurück zum Zitat Volkomorov V, Grigoryeva E, Krasnov G, Litviakov N, Tsyganov M, Karbyshev M, et al. Search for potential gastric cancer markers using miRNA databases and gene expression analysis. Exp Oncol. 2013;35(1):2–7.PubMed Volkomorov V, Grigoryeva E, Krasnov G, Litviakov N, Tsyganov M, Karbyshev M, et al. Search for potential gastric cancer markers using miRNA databases and gene expression analysis. Exp Oncol. 2013;35(1):2–7.PubMed
21.
Zurück zum Zitat Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, et al. Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol. 2004;39(4):380–4.CrossRefPubMed Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, et al. Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol. 2004;39(4):380–4.CrossRefPubMed
24.
Zurück zum Zitat Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin. 2009;41(8):648–56.CrossRefPubMed Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin. 2009;41(8):648–56.CrossRefPubMed
29.
Zurück zum Zitat Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881–9.CrossRefPubMedPubMedCentral Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881–9.CrossRefPubMedPubMedCentral
Metadaten
Titel
Disregulation of miR-216a and miR-217 in Gastric Cancer and Their Clinical Significance
verfasst von
Reza Safaralizadeh
Naser Ajami
Masoumeh Nemati
Mohammadali Hosseinpourfeizi
Arash Azimzadeh Isfanjani
Seyed-Yaghob Moaddab
Publikationsdatum
27.11.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2019
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-0019-6

Weitere Artikel der Ausgabe 1/2019

Journal of Gastrointestinal Cancer 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.